Difference between revisions of "Jesse 2009 CNS Neurosci Ther"
(Created page with "{{Publication |title=Jesse S, Steinacker P, Lehnert S, Gillardon F, Hengerer B, Otto M (2009) Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson deme...") |
Bader Helga (talk | contribs) |
||
| (12 intermediate revisions by 6 users not shown) | |||
| Line 1: | Line 1: | ||
{{Publication | {{Publication | ||
|title=Jesse S, Steinacker P, Lehnert S, Gillardon F, Hengerer B, Otto M (2009) Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review. CNS Neurosci | |title=Jesse S, Steinacker P, Lehnert S, Gillardon F, Hengerer B, Otto M (2009) Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review. CNS Neurosci Ther 15:157-82. | ||
|authors=Jesse S, Steinacker P, Lehnert S, Gillardon F, Hengerer B, Otto M | |info=[http://www.ncbi.nlm.nih.gov/pubmed/19298613 PMID: 19298613 Open Access] | ||
|authors=Jesse S, Steinacker P, Lehnert S, Gillardon F, Hengerer B, Otto M | |||
|year=2009 | |year=2009 | ||
|journal=CNS | |journal=CNS Neurosci Ther | ||
|abstract=The diagnosis of Parkinson disease (PD) is rendered on the basis of clinical parameters, whereby laboratory chemical tests or morphological imaging is only called upon to exclude other neurodegenerative diseases. The differentiation between PD and other diseases of the basal ganglia, especially the postsynaptic Parkinson syndromes multisystem atrophy (MSA) and progressive supranuclear palsy (PSP), is of decisive importance, on the one hand, for the response to an appropriate therapy, and on the other hand, for the respective prognosis of the disease. However, particularly at the onset of symptoms, it is difficult to precisely distinguish these diseases from each other, presenting with an akinetic-rigid syndrome. It is not yet possible to conduct a neurochemical differentiation of Parkinson syndromes. Therefore, a reliable biomarker is still to be found that might predict the development of Parkinson dementia. Since this situation is currently the subject of various different studies, the following synopsis is intended to provide a brief summary of the investigations addressing the field of the early neurochemical differential diagnosis of Parkinson syndromes and the early diagnosis of Parkinson dementia, from direct α-synuclein detection to proteomic approaches. In addition, an overview of the tested biomarkers will be given with regard to their possible introduction as a screening method. | |abstract=The diagnosis of Parkinson disease (PD) is rendered on the basis of clinical parameters, whereby laboratory chemical tests or morphological imaging is only called upon to exclude other neurodegenerative diseases. The differentiation between PD and other diseases of the basal ganglia, especially the postsynaptic Parkinson syndromes multisystem atrophy (MSA) and progressive supranuclear palsy (PSP), is of decisive importance, on the one hand, for the response to an appropriate therapy, and on the other hand, for the respective prognosis of the disease. However, particularly at the onset of symptoms, it is difficult to precisely distinguish these diseases from each other, presenting with an akinetic-rigid syndrome. It is not yet possible to conduct a neurochemical differentiation of Parkinson syndromes. Therefore, a reliable biomarker is still to be found that might predict the development of Parkinson dementia. Since this situation is currently the subject of various different studies, the following synopsis is intended to provide a brief summary of the investigations addressing the field of the early neurochemical differential diagnosis of Parkinson syndromes and the early diagnosis of Parkinson dementia, from direct α-synuclein detection to proteomic approaches. In addition, an overview of the tested biomarkers will be given with regard to their possible introduction as a screening method. | ||
|keywords= | |keywords=Differential diagnosis, Multisystem atrophy, Neurochemical diagnosis, Parkinson dementia, Parkinson disease, Progressive supranuclear palsy | ||
| | |discipline=Biomedicine | ||
}} | }} | ||
{{Labeling | {{Labeling | ||
|enzymes=Marker enzyme | |||
|injuries=Mitochondrial disease | |||
|diseases=Parkinson's | |||
|couplingstates=OXPHOS | |||
|instruments=Oxygraph-2k | |instruments=Oxygraph-2k | ||
| | |discipline=Biomedicine | ||
}} | }} | ||
Latest revision as of 14:40, 20 March 2015
| Jesse S, Steinacker P, Lehnert S, Gillardon F, Hengerer B, Otto M (2009) Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review. CNS Neurosci Ther 15:157-82. |
Jesse S, Steinacker P, Lehnert S, Gillardon F, Hengerer B, Otto M (2009) CNS Neurosci Ther
Abstract: The diagnosis of Parkinson disease (PD) is rendered on the basis of clinical parameters, whereby laboratory chemical tests or morphological imaging is only called upon to exclude other neurodegenerative diseases. The differentiation between PD and other diseases of the basal ganglia, especially the postsynaptic Parkinson syndromes multisystem atrophy (MSA) and progressive supranuclear palsy (PSP), is of decisive importance, on the one hand, for the response to an appropriate therapy, and on the other hand, for the respective prognosis of the disease. However, particularly at the onset of symptoms, it is difficult to precisely distinguish these diseases from each other, presenting with an akinetic-rigid syndrome. It is not yet possible to conduct a neurochemical differentiation of Parkinson syndromes. Therefore, a reliable biomarker is still to be found that might predict the development of Parkinson dementia. Since this situation is currently the subject of various different studies, the following synopsis is intended to provide a brief summary of the investigations addressing the field of the early neurochemical differential diagnosis of Parkinson syndromes and the early diagnosis of Parkinson dementia, from direct α-synuclein detection to proteomic approaches. In addition, an overview of the tested biomarkers will be given with regard to their possible introduction as a screening method. • Keywords: Differential diagnosis, Multisystem atrophy, Neurochemical diagnosis, Parkinson dementia, Parkinson disease, Progressive supranuclear palsy
Labels:
Pathology: Parkinson's
Stress:Mitochondrial disease
Enzyme: Marker enzyme
Coupling state: OXPHOS
HRR: Oxygraph-2k
